(IN BRIEF) EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss biotechnology company’s USD 152 million Series B financing. The funding will support the global Phase 3 HEROIC study of engasertib, Vaderis’ lead … Read the full press release →
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Science, Sweden, Switzerland, Technology
Tagged Azmi Nabulsi, biotechnology investment, Christoph Broja, chronic anemia, clinical-stage biotechnology, Droia, engasertib, epistaxis, EQT Life Sciences, EQT Life Sciences Backs Vaderis Therapeutics’ Phase 3 Development of Engasertib, EQT Life Sciences Invests USD 17.5 Million in Vaderis Therapeutics Series B, global Phase 3 trial, Goldman Sachs Alternatives, hereditary hemorrhagic telangiectasia, HEROIC study, HHT, inherited blood vessel disorder, Kalehua Capital, late-stage clinical development, long-term extension data, Medicxi, no approved therapies, Omega Funds, Patient Advocacy, Perceptive Advisors, phase 3 study, pivotal development, proof-of-concept data, rare disease therapy, rare genetic vascular disease, rare vascular disease, regulatory approval, Series B financing, severe nosebleeds, Swiss biotechnology company, targeted therapies, TCGX, The New England Journal of Medicine, USD 152 million financing, USD 17.5 million investment, Vaderis Therapeutics, Vaderis Therapeutics Secures USD 152 Million Series B to Advance HHT Therapy, vascular abnormalities
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Digi Communications NV announces availability of Digi Spain’s H1 2026 financial results presentation
Load more...
